Assessment of Liver Stiffness among Chronic Hepatitis C Patients after Oral Antiviral Drugs in Zagazig University Hospitals | ||
| Zagazig University Medical Journal | ||
| Article 2, Volume 25, Issue 5, September 2019, Pages 630-638 PDF (159.5 K) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/zumj.2019.11090.11450 | ||
| Authors | ||
| Mohammed Hisham Mounir; Amany Mohammed Ibrahim; Sameh Saber Bayiomy; Hany Mostafa Omar | ||
| Abstract | ||
| Background: The hepatitis C virus (HCV) may be an important explanation for hepatic pathology, cirrhosis, and hepatocellular carcinoma. The aim of the study wasto assess the liver stiffness before and after oral antiviral medication in chronic viral hepatitis c patients attending Zagazig University Hospitals. Methods: This study included forty three Egyptian patients with HCV infection diagnosed by HCV RNA real time quantitative PCR whose ages were ranged from 29-71 , All patients took anti-viral treatment according to the rules of the committee responsible for hepatitis c virus control in Egypt. Treatment regimens included: Sofosbuvir, daclatasvir and ribavirin (RBV). The patients were collected and followed up in the period between April 2017 and August 2018. , radiological tool liver transient elastography (TE) and laboratory tests APRI, FIB4 test were done for all patients.Results: There were improvements in liver stiffness measurements,APRI,FIB4 test hemoglobin, fasting blood sugar , platelets count, and ALT, AST levels in patients who achieved a 48-week sustained infectious agent response. The failure to achieve improvement within the level of liver stiffness was related to treatment failure. Conclusions: Treatment with sofosbuvir drug regimen makes significant decrease in liver stiffness measurements and fibrosis indices. | ||
| Keywords | ||
| Liver Stiffness; FibroScan; Direct antivirals | ||
|
Statistics Article View: 332 PDF Download: 459 |
||
